Regeneron Pharmaceuticals CEO Sheds Light On The Company's Recently Approved Cholesterol-Lowering Drug 'Praluent' And Its Pricing

Loading...
Loading...

Regeneron Pharmaceuticals Inc REGN's cholesterol-lowering drug Praluent recently got approved by the U.S. Food and Drug Administration (FDA).

 

Leonard Schleifer, Regeneron president & CEO, was on CNBC Monday to discuss Praluent and its pricing.

 

Doesn't Compete With Statins

 

"Let's face it, statins are great drugs and they have been around for decades and they should be front-line here," Schleifer said. "But some people with cardiovascular disease or heredity high-cholesterol, they can't get their cholesterol low enough on a statin or they can't take enough of a statin to get it down and that's where our drug might come in."

 

Pricing

 

On the drugs pricing, Schleifer said, "Actually our price is the lowest price of any self administered human monoclonal antibody. So, if you look at the other self administered monoclonals such as drugs for rheumatoid arthritis, they are 2 or 3 times what our drug is going for. [I mean], we approach the pricing of the drug based on value delivered."

 

Schleifer highlighted how the company has priced Praluent based on value delivered, saying, "I think a lot of thought went into the pricing of Praluent and it is a good case study. And, I think, there are 3 ways you can price drugs - you can price drugs by what the market will bear, you can price it based on what you think should be a fair rate of return or you can price it based on the value delivered. We are moving rapidly and we believe you should be in the last category based on the value you deliver.


Schleifer also remarked, "well overtime...if the volumes become much higher, prices can be adjusted. That's not an issue."

Loading...
Loading...
Posted In: CNBCMedia
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...